


Fig. S1



**Fig. S1. Antitumor effect for the Irbinecetin-Gemcitabine combination at different dose levels.** Tumor growth (median) curves for mice bearing SW-1190 (**A, C, E**) or MIA PaCa-2 (**B, D, F**) tumors treated with PM01183, Gemcitabine and PM01183+Gemcitabine are displayed. Nude athymic mice bearing subcutaneous tumors (SW-1990 or MIA PaCa-2) sized ca. 150 mm<sup>3</sup>, were randomly allocated to treatment groups ( $N=7$ /group): (**A, B**), PM01183 at four dose levels, namely MTD (0.180 mgKg<sup>-1</sup>), 0.75 MTD (0.135 mgKg<sup>-1</sup>), 0.5 MTD (0.09 mgKg<sup>-1</sup>), and 0.25 MTD (0.045 mgKg<sup>-1</sup>); (**C, D**), Gemcitabine, at four dose levels MTD (180.0 mgKg<sup>-1</sup>), 0.75 MTD (135.0 mgKg<sup>-1</sup>), 0.5 MTD (90.0 mgKg<sup>-1</sup>), and 0.25 MTD (45.0 mgKg<sup>-1</sup>); and PM01183 plus gemcitabine (**E, F**), administered with the combination at (1 + 1), (0.75 + 0.75), (0.50 + 0.50), and (0.25 + 0.25) of MTD ratios.